You can search in free text – simply type the disease, drug, company name, or other detail into the Search bar below and click Apply
Displaying 450 of 472

Armata Pharmaceuticals, Inc.

EA Page: https://www.armatapharma.com/contact-us/expanded-access-policy/

Stanford University - Center for Definitive and Curative Medicine

EA Page: https://med.stanford.edu/cdcm.html

Stanford University - Center for Definitive and Curative Medicine

Terremoto Biosciences

EA Page: https://terremotobio.com/expanded-access-policy/

Nouscom AG

EA Page: https://nouscom.com/pipeline/nous-209-expandedaccesspolicy/

Revolution Medicines, Incorporated

EA Page: https://www.revmed.com/expanded-access-policy/

Matisse Pharmaceuticals B.V.

Novo Nordisk

EA Page: http://www.novonordisk-us.com/whoweare/about-novo-nordisk/expanded-access.html

DBV Technologies

Expanded Access Protocol of Viaskin® Peanut (DBV712) in Peanut-allergic Children

Conditions: Peanut Allergy

This is an open label expanded access program for male and female patients 2 years orolder, to provide continued desensitization treatment with DBV712 250 mcg.

Matrix Biomed, Inc.

Treatment of Metastatic Cancer in Terminally Diagnosed Patients

Conditions: Metastatic Cancer

The objective is to provide terminally diagnosed patients with a last line of treatmentwhile improving overall quality of life. Tempol can be added to any chemotherapy regimento potentially reduce side effects and overcome chemoresistance.